These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15884403)

  • 1. [Antithrombotic therapy during percutaneous coronary interventions].
    Verheugt FW; Dieker H; Aengevaeren WR
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):912-6. PubMed ID: 15884403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Popma JJ; Berger P; Ohman EM; Harrington RA; Grines C; Weitz JI
    Chest; 2004 Sep; 126(3 Suppl):576S-599S. PubMed ID: 15383485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of improved antithrombotic and antiplatelet agents: genesis of the Comparison of Abciximab Complications with Hirulog [and back-Up Abciximab] Events Trial (CACHET).
    Topol EJ
    Am J Cardiol; 1998 Oct; 82(8B):63P-68P. PubMed ID: 9809894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriate antiplatelet and antithrombotic therapy in patients with acute coronary syndromes: recent updates to the ACC/AHA guidelines.
    Mehta SR;
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():27E-34E; quiz 35E. PubMed ID: 12668860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
    Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
    Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
    Parodi G; Sciagrà R; Migliorini A; Memisha G; Moschi G; Valenti R; Pupi A; Antoniucci D
    Am Heart J; 2005 Aug; 150(2):220. PubMed ID: 16086921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
    Kastrati A; Mehilli J; Neumann FJ; Dotzer F; ten Berg J; Bollwein H; Graf I; Ibrahim M; Pache J; Seyfarth M; Schühlen H; Dirschinger J; Berger PB; Schömig A;
    JAMA; 2006 Apr; 295(13):1531-8. PubMed ID: 16533938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.
    Furman MI; Frelinger III AL; Michelson AD
    Curr Cardiol Rep; 2000 Sep; 2(5):386-94. PubMed ID: 10980905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New antiplatelet agents.
    White HD; French JK; Ellis CJ
    Aust N Z J Med; 1998 Aug; 28(4):558-64. PubMed ID: 9777140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
    Radke PW; Schunkert H
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S204-7. PubMed ID: 17109249
    [No Abstract]   [Full Text] [Related]  

  • 14. Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment.
    Buller CE; Pate GE; Armstrong PW; O'Neill BJ; Webb JG; Gallo R; Welsh RC
    Can J Cardiol; 2006 May; 22(6):511-5. PubMed ID: 16685318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in antithrombotic therapy of acute myocardial infarction.
    Gensini GF; Comeglio M; Falai M
    Am Heart J; 1999 Aug; 138(2 Pt 2):S171-6. PubMed ID: 10426878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic therapy in cardiac stent patients.
    Cannan CR
    Curr Cardiol Rep; 2001 Jan; 3(1):78-84. PubMed ID: 11139803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of platelet surface receptors and early changes in platelet function in patients with STEMI treated with abciximab and clopidogrel versus clopidogrel alone.
    Konopka A; Spychalska J; Sitkiewicz D; Zdebska E; Pilichowska I; Piotrowski W; Stepińska J
    Am J Cardiovasc Drugs; 2007; 7(6):433-9. PubMed ID: 18076210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platelet antiaggregation treatment in the aftermath of GUSTO IV, TARGET, TACTICS, and CURE trials].
    Bassand JP
    Rev Esp Cardiol; 2002 Jul; 55(7):697-702. PubMed ID: 12113695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight heparins in the cardiac catheterization laboratory.
    Montalescot G; Cohen M
    J Thromb Thrombolysis; 1999 Jun; 7(3):319-23. PubMed ID: 10373715
    [No Abstract]   [Full Text] [Related]  

  • 20. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.